Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1062 | 1062 | 1051 | 1370 | 1561 | 2464 |
Fund Return | 6.22% | 6.22% | 5.11% | 11.07% | 9.31% | 9.44% |
Place in category | 707 | 707 | 687 | 56 | 151 | 145 |
% in Category | 69 | 69 | 77 | 12 | 36 | 51 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Seligson Co Global Top 25 Brands Fu | 703.2M | 6.90 | 9.10 | 13.03 | ||
Seligson & Co Global Top 25 Brands | 703.2M | 6.91 | 9.10 | 13.00 | ||
Seligson North American B | 470.11M | 17.21 | 15.66 | 15.17 | ||
Seligson & Co North American A | 470.11M | 17.21 | 15.67 | 15.19 | ||
Seligson & Co Europe Index Fund A | 279.5M | 8.62 | 9.19 | 7.26 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Danske Invest MediLife T | 591.15K | 8.06 | 10.80 | 11.54 | ||
Danske Invest MediLife K | 88.54M | 8.06 | 10.79 | 11.54 | ||
Seligson Co Global Top 25 Pharma A | 269.22M | 6.21 | 11.06 | 9.41 | ||
LahiTapiola Hyvinvointi A | 148.91M | 7.02 | 2.36 | 9.27 | ||
LahiTapiola Hyvinvointi B | 148.91M | 7.02 | 2.37 | 9.27 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Merck&Co | US58933Y1055 | 7.84 | 131.19 | +0.36% | |
J&J | US4781601046 | 6.47 | 146.13 | -0.47% | |
Pfizer | US7170811035 | 6.25 | 25.38 | +0.48% | |
Novartis | CH0012005267 | 6.18 | 89.50 | -0.56% | |
Roche Holding Participation | CH0012032048 | 5.63 | 221.00 | +1.01% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Neutral |
Technical Indicators | Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review